Publications - Page 29 sur 57 - RespiFIL - Filière de santé des maladies respiratoires rares

Voici les publications scientifiques relatives aux maladies respiratoires rares auxquelles les membres de la filière ont contribué, classées par groupes de pathologies (depuis juillet 2021).

Hypertension pulmonaire (HTP)
New trends in pulmonary hypertension.

Cullivan S, Gaine S, Sitbon O.

Eur Respir Rev. 2023 Feb 21;32(167):220211.
Hypertension pulmonaire (HTP)
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.

Gillies H, Niven R, Dake BT, Chakinala MM, Feldman JP, Hill NS, Hoeper MM, Humbert M, McLaughlin VV, Kankam M.

ERJ Open Res. 2023 Mar 13;9(2):00433-2022.
Hypertension pulmonaire (HTP)
Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.

Mumby S, Perros F, Grynblat J, Manaud G, Papi A, Casolari P, Caramori G, Humbert M, John Wort S, Adcock IM.

Respir Res. 2023 Jul 29;24(1):193.
Hypertension pulmonaire (HTP)
The ‘Ten Commandments’ of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

Rosenkranz S, Delcroix M, Giannakoulas G, Hoeper MM, Kovacs G, Humbert M.

Eur Heart J. 2023 Mar 7;44(10):792-793.
Hypertension pulmonaire (HTP)
Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR Study

Gomberg-Maitland M, McLaughlin VV, Badesch DB, Ghofrani HA, Hoeper MM, Humbert M, Preston IR, Souza R, Waxman AB, de Oliveira Pena J, Lu JT, Manimaran S, Gibbs JSR.

JACC Heart Fail. 2023 Jul 12:S2213-1779(23)00309-8.
Hypertension pulmonaire (HTP)
European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.

Aktaa S, Gale CP, Brida M, Giannakoulas G, Kovacs G, Adir Y, Benza RL, Böhm M, Coats A, D'Alto M, Escribano-Subias P, Ferrari P, Galiè N, Gibbs JSR, Gin-Sing W, Hoeper MM, Humbert M, Lang IM, Maron BA, Meszaros G, Vonk Noordegraaf A, Price LC, Pepke-Zaba J, Rådegran G, Reis A, Sitbon O, Torbicki A, Ulrich S, Rosenkranz S, Delcroix M.

Eur J Heart Fail. 2023 Apr;25(4):469-477.
Hypertension pulmonaire (HTP)
PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.

Weatherald J, Humbert M.

Respirology. 2023 Mar;28(3):212-214.
Pneumopathies interstitielles diffuses (PID)
Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud.

Cottin V, Valenzuela C, Humbert M.

Eur Respir J. 2023 Jun 29;61(6):2300944.
Hypertension pulmonaire (HTP)
Management of Pulmonary Arterial Hypertension.

Weatherald J, Varughese RA, Liu J, Humbert M.

Semin Respir Crit Care Med. 2023 Jun 27.
Hypertension pulmonaire (HTP)
Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension.

Weatherald J, Zanini U, Humbert M.

Am J Respir Crit Care Med. 2023 Aug 1;208(3):231-233.

FILTRER :

Par mot clé

Par maladies

Réinitialiser les filtres

New trends in pulmonary hypertension.

AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study.

Differential responses of pulmonary vascular cells from PAH patients and controls to TNFα and the effect of the BET inhibitor JQ1.

The ‘Ten Commandments’ of the 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.

Long-Term Effects of Sotatercept on Right Ventricular Function: Results From the PULSAR Study

European Society of Cardiology quality indicators for the care and outcomes of adults with pulmonary arterial hypertension. Developed in collaboration with the Heart Failure Association of the European Society of Cardiology.

PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.

Inhaled treprostinil for interstitial lung disease-associated pulmonary hypertension: a silver lining on a very dark cloud.

Management of Pulmonary Arterial Hypertension.

Illuminating the Importance of Pulmonary Arterial Compliance in Pulmonary Hypertension.